A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

Study Summary

This is a study to evaluate the safety and preliminary anti-tumor activity of STRO-004 in adults with metastatic cancer. This study includes 3 parts: * Part 1A is a dose escalation study of STRO-004 monotherapy in selected tumor types known to commonly express Tissue Factor (TF). * Part 1B is a cohort expansion in 1 or more types of cancer to further evaluate a STRO-004 monotherapy dose, determine the best dose for use in later phases, and examine anti-tumor activity. * Part 1C is a dose escalation of STRO-004 combined with pembrolizumab to determine tolerability and preliminary anti-tumor activity of both drugs used together.

Conditions

Head and Neck Squamous Cell Carcinoma HNSCC Non-Small Cell Lung Cancer NSCLC Esophageal Cancer Gastric Cancer Colorectal Cancer Pancreatic Ductal Adenocarcinoma (PDAC)Cervical Cancer Endometrial Cancer Urothelial Cancer

Interventions / Drugs

STRO-004 Pembrolizumab

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment200 participants

Primary Completion—

Lead SponsorSutro Biopharma, Inc.

Data Retrieved2026-04-11 04:28:24.696016+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.